Golchin et al. reported that combination therapy using Oxa with anti-PD-L1 increased survival and inhibited tumor growth better than either anti-PD-L1 or Oxa alone in CT26-established syngeneic mouse models [47]. Here, DDX53 is linked to neoplasm.